Olivier Corminboeuf

This inventor holds 23 USPTO granted patents and 3 published patent applications, plus 5 CIPO patents and 22 EPO patents, primarily in Receptor Modulators. Top assignees: Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd. Active years: 2010-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olivier Corminboeuf. Retrieved from https://idiyas.com/inventor/olivier-corminboeuf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 3)

% Patents Active = 30.4

CIPO Patents = 5 (Patent Applications = 9)

EPO Patents = 22 (Patent Applications = 22)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 49(Granted Patents)

Company Filing History:

17 out of 217

Actelion Pharmaceuticals Ltd

patents

6 out of 81

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2010-2024

Loading Chart...

Areas of Expertise:

PGE2 Receptor

ALX Receptor

Indole Derivatives

Pyrimidine Derivatives

Spiroheptane Derivatives

Aminotriazole Derivatives

Benzimidazole Derivatives

Piperazine Compounds

Fluorinated Compounds

Antimalarial Agents

Renin Inhibitors

Bicyclononene Derivatives

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12011444 - N-substituted indole derivatives as PGE2 receptor modulators (2024-06-18),

2. 11839613 - Pyrimidine derivatives as PGE2 receptor modulators (2023-12-12),

3. 11712438 - Phenyl derivatives as PGE2 receptor modulators (2023-08-01),

4. 11446298 - Pyrimidine derivatives (2022-09-20),

5. 11325899 - Benzofurane and benzothiophene derivatives as PGE2 receptor modulators (2022-05-10),

6. 11241431 - N-substituted indole derivatives as PGE2 receptor modulators (2022-02-08),

7. 9676761 - Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists (2017-06-13),

8. 9663473 - Benzimidazolyl-methyl urea derivatives as ALX receptor agonists (2017-05-30),

9. 9533964 - Piperazine substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists (2017-01-03),

10. 9346793 - Hydroxylated aminotriazole derivatives as ALX receptor agonists (2016-05-24),

11. 9284288 - 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists (2016-03-15),

12. 9187435 - Bridged Spiro[2.4]heptane ester derivatives (2015-11-17),

13. 9139524 - Fluorinated bridged spiro[2.4]heptane derivatives as ALX receptor agonists (2015-09-22),

14. 8889688 - Piperazines as antimalarial agents (2014-11-18),

15. 8846733 - Oxazolyl-methylether derivatives as ALX receptor agonists (2014-09-30),

Title: Inventor Olivier Corminboeuf

Introduction: Olivier Corminboeuf is a renowned inventor hailing from Allschwil, Switzerland. He has made significant contributions to the field of innovation with his groundbreaking ideas and inventions.

Latest Patents: Olivier Corminboeuf holds several patents in various industries, including technology, healthcare, and sustainability. His recent patents focus on renewable energy solutions and advanced medical devices.

Career Highlights: With a career spanning over two decades, Olivier Corminboeuf has worked with leading research institutions and companies to bring his inventions to life. He has a proven track record of turning innovative ideas into successful products.

Collaborations: Throughout his career, Olivier Corminboeuf has collaborated with top engineers, scientists, and designers to enhance the impact of his inventions. His ability to work in multidisciplinary teams has led to the development of cutting-edge technologies.

Conclusion: Olivier Corminboeuf's passion for innovation and dedication to creating a positive change in the world through his inventions make him a standout figure in the field of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators.

Profile summary based on public USPTO records.